Beam Therapeutics (BEAM) Equity Income (2020 - 2026)

Beam Therapeutics (BEAM) has 7 years of Equity Income data on file, last reported at $16000.0 in Q1 2026.

• Equity Income for Q1 2026 came in at $16000.0, up 100.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.0 million (up 147.1% YoY), and the FY2025 annual result was $3.9 million, up 127.97% from the prior year.
• Equity Income grew to $16000.0 in Q1 2026 per BEAM's latest filing, from -$3.3 million in the prior quarter.
• Over five years, Equity Income peaked at $45.7 million in Q4 2022 and troughed at -$12.8 million in Q1 2023.
• A 5-year average of $917352.9 and a median of -$2.1 million in 2024 frame the typical range for Equity Income.
• On a YoY basis, Equity Income climbed as much as 1170.26% in 2022 and fell as far as 839.65% in 2022.
• A 5-year view of Equity Income shows it stood at $45.7 million in 2022, then sank by 101.58% to -$722000.0 in 2023, then slumped by 50.97% to -$1.1 million in 2024, then slumped by 205.41% to -$3.3 million in 2025, then surged by 100.48% to $16000.0 in 2026.
• Business Quant data shows BEAM's Equity Income at $16000.0 in Q1 2026, -$3.3 million in Q4 2025, and $4.9 million in Q3 2025.